A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune

OBJECTIVES: Therapeutic HIV vaccination during the time of virologic suppression may delay or blunt viral load rebound after interruption of antiretroviral therapy (ART). The use of ALVAC, to enhance cytotoxic T-lymphocyte responses, with Remune, which provides CD4 T-cell help, may induce anti-HIV responses capable of controlling viral replication. METHODS: CTN173 was a randomized, placebo-controlled double-blind study in which effectively …